Expert Council resolution “Optimization of diagnosis and therapy of hyperuricemia”
Drapkina O.M., Mazurov V.I., Nasonov E.L., Lila A.M., Gaydukova I.Z., Eliseev M.S., Nedogoda S.V., Ostroumova O.D., Trofimov E.A., Bashkinov R.A.
EXPERT COUNCIL MEMBERS:
DRAPKINA O.M., MD, Dr. Sci. (Medicine), professor, academician of RAS, director of National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of Russia, chief external expert in therapy and general medical practice of the Ministry of Healthcare of Russia, president of Russian Scientific Medical Society of Internal Medicine (RSMSIM), president of Russian Society for the Prevention of Non-Infectious Diseases, Honored Doctor of the Russian Federation, Moscow
MAZUROV V.I., MD, Dr. Sci. (Medicine), professor, academician of RAS, chief scientific advisor, director of the Research Institute of Rheumatology, head of the Department of therapy and rheumatology named after E.E. Eichwald of I.I. Mechnikov North-Western State Medical University, vice president of Russian Scientific Medical Society of Internal Medicine (RSMSIM), first vice president of the Russian Association of Rheumatologists, Honored Scientist of the Russian Federation, Saint Petersburg
NASONOV E.L., MD, Dr. Sci. (Medicine), professor, academician of RAS, academic advisor of V.A. Nasonova Research Institute of Rheumatology, president of the Russian Association of Rheumatologists, Honored Scientist of the Russian Federation, Moscow
LILA A.M., MD, Dr. Sci. (Medicine), professor, corresponding member of RAS, director of V.A. Nasonova Research Institute of Rheumatology, head of the Department of rheumatology of Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia, chief external expert-rheumatologist of the Ministry of Healthcare of Russia, Honored Doctor of the Russian Federation, Moscow
GAYDUKOVA I.Z., MD, Dr. Sci. (Medicine), associate professor, deputy director of the Research Institute of Rheumatology, professor of the Department of therapy and rheumatology named after E.E. Eichwald of I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia, Saint Petersburg
ELISEEV M.S., MD, PhD (Medicine), head of the Department of microcrystalline arthritis of V.A. Nasonova Research Institute of Rheumatology, Moscow
NEDOGODA S.V., MD, Dr. Sci. (Medicine), professor, head of the Department of internal medicine of the Institute of Continuous Medical and Pharmaceutical Education of Volgograd State Medical University of the Ministry of Healthcare of Russia, vice president of the Russian Society of Cardiology, Honored Doctor of the Russian Federation, Volgograd
OSTROUMOVA O.D., MD, Dr. Sci. (Medicine), professor, head of the Department of therapy and polymorbid pathology named after academician M.S. Vovsi of Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia, professor of the Department of clinical pharmacology and propaedeutics of internal medicine of I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University), Moscow
TROFIMOV E.A., MD, Dr. Sci. (Medicine), associate professor, deputy director of the Research Institute of Rheumatology, professor of the Department of therapy and rheumatology named after E.E. Eichwald of I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia, Saint Petersburg
BASHKINOV R.A., MD, PhD (Medicine), assistant at the Department of therapy and rheumatology named after E.E. Eichwald of I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia, Saint Petersburg
Abstract. In November 2025, a meeting of the Expert Council as part of the XX National Congress of Internal Medicine took place. The discussion was focused on hyperuricemia (HU), an important factor in the development and progression of a wide range of medical diseases that negatively contributes to cardiovascular and overall mortality increasing. Leading Russian specialists in internal medicine discussed the role of elevated serum uric acid levels in the etiopathogenesis of socially significant chronic non-communicable diseases, and outlined key aspects of diagnosis, as well as non-pharmacological and pharmacological treatment of HU. Following the meeting, it was adopted a resolution concerning the necessity to establish a Working Group and develop national clinical guidelines for HU diagnosis and treatment.
The resolution of the Expert Council was approved on 19.11.2025 by the Bureau of the presidium of Russian Scientific Medical Society of Internal Medicine (RSMSIM).
Keywords
hyperuricemia
uric acid
cardiometabolic risk factors
comorbidity
References
1. Драпкина О.М., Мазуров В.И., Мартынов А.И., Гайдукова И.З., Дупляков Д.В., Невзорова В.А. с соавт. «В фокусе гиперурикемия». Резолюция Совета экспертов. Кардиоваскулярная терапия и профилактика. 2023;22(4):77–84. (Drapkina OM, Mazurov VI, Martynov AI, Gaidukova IZ, Duplyakov DV, Nevzorova VA et al. “Focus on hyperuricemia”. The resolution of the Expert Council. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2023;22(4):77–84 (In Russ.)).
EDN: KRCKAU. https://doi.org/10.15829/1728-8800-2023-3564
2. Драпкина О.М., Мазуров В.И., Мартынов А.И., Насонов Е.Л., Сайганов С.А., Лила А.М. с соавт. Консенсус для врачей по ведению пациентов с бессимптомной гиперурикемией в общетерапевтической практике. Кардиоваскулярная терапия и профилактика. 2024;23(1):89–104. (Drapkina OM, Mazurov VI, Martynov AI, Nasonov EL, Saiganov SA, Lila AM et al. Consensus statement on the management of patients with asymptomatic hyperuricemia in general medical practice. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2024;23(1):89–104 (In Russ.)).
EDN: WXKMIG. https://doi.org/10.15829/1728-8800-2024-3737
3. Шальнова С.А., Деев А.Д., Артамонова Г.В., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В. с соавт. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ). Рациональная фармакотерапия в кардиологии. 2014;10(2):153–159. (Shalnova SA, Deev AD, Artamonov GV, Duplyakov DV, Efanov AYu, Zhernakova YuV et al. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF epidemiological study). Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2014;10(2):153–159 (In Russ.)). EDN: SCOUHN.
4. Шальнова С.А., Имаева А.Э., Куценко В.А., Баланова Ю.А., Капустина А.В., Шепель Р.Н., Драпкина О.М. Гиперурикемия и артериальная гипертония у лиц трудоспособного возраста: результаты популяционного исследования. Кардиоваскулярная терапия и профилактика. 2023;22(S9):93–102. (Shalnova SA, Imaeva AE, Kutsenko VA, Balanova YuA, Kapustina AV, Shepel RN, Drapkina OM. Hyperuricemia and hypertension in working-age people: Results of a population study. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2023;22(S9):93–102 (In Russ.)).
EDN: TAHKSZ. https://doi.org/10.15829/1728-8800-2023-3783
5. Maloberti A, Mengozzi A, Russo E, Cicero AFG, Angeli F, Agabiti Rosei E et al.; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). The results of the URRAH (Uric Acid Right for Heart Health) project: A focus on hyperuricemia in relation to cardiovascular and kidney disease and its role in metabolic dysregulation. High Blood Press Cardiovasc Prev. 2023;30(5):411–25.
PMID: 37792253. PMCID: PMC10600296. https://doi.org/10.1007/s40292-023-00602-4
6. Kuwabara M, Niwa K, Hisatome I, Nakagawa T, Roncal-Jimenez CA, Andres-Hernando A et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: Five-year Japanese cohort study. Hypertension. 2017;69(6):1036–44.
PMID: 28396536. PMCID: PMC5426964. https://doi.org/10.1161/HYPERTENSIONAHA.116.08998
7. Wang H, Zhang H, Sun L, Guo W. Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases. Am J Transl Res. 2018;10(9):2749–63.
PMID: 30323864. PMCID: PMC6176241.
8. Мазуров В.И., Драпкина О.М., Мартынов А.И., Сайганов С.А., Башкинов Р.А., Гайдукова И.З. с соавт. Метаанализ наблюдательных когортных исследований о взаимосвязях бессимптомной гиперурикемии с хронической болезнью почек. Терапия. 2023;9(10):21–39. (Mazurov VI, Drapkina OM, Martynov AI, Sayganov SA, Bashkinov RA, Gaydukova IZ et al. Meta-analysis of observational cohort studies on the relationships of asymptomatic hyperuricemia with chronic kidney disease. Terapiya = Therapy. 2023;9(10):21–39 (In Russ.)).
EDN: MWVPUQ. https://doi.org/10.18565/therapy.2023.10.21-39
9. Мазуров В.И., Башкинов Р.А., Гайдукова И.З., Фонтуренко А.Ю. Влияние бессимптомной гиперурикемии на коморбидные заболевания и возможности ее коррекции. РМЖ. 2021;29(7):24–30. (Mazurov VI, Bashkinov RA, Gaydukova IZ, Fonturenko AYu. The effect of asymptomatic hyperuricemia on comorbidities and the possibility of its correction. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2021;29(7):24–30 (In Russ.)). EDN: EZWQOO.
10. Башкинов Р.А., Мазуров В.И., Гайдукова И.З., Инамова О.В., Петрова М.С. Особенности течения остеоартрита у пациентов с бессимптомной гиперурикемией. Терапия. 2025;11(1):16–28. (Bashkinov RA, Mazurov VI, Gaydukova IZ, Inamova OV, Petrova MS. Features of the course of osteoarthritis in patients with asymptomatic hyperuricemia. Terapiya = Therapy. 2025;11(1):16–28 (In Russ.)).
EDN: AAFGTW. https://doi.org/10.18565/therapy.2025.1.16-28
11. Цинзерлинг А.Ю., Мазуров В.И., Гайдукова И.З., Петрова М.С., Инамова О.В., Башкинов Р.А., Гончар Н.Т. Бессимптомная гиперурикемия и рентгенологическое прогрессирование ревматоидного артрита. РМЖ. Медицинское обозрение. 2022;6(8):470–479. (Tsinserling AYu, Mazurov VI, Gaydukova IZ, Petrova MS, Inamova OV, Bashkinov RA et al. Asymptomatic hyperuricemia and radiographic progression of rheumatoid arthritis. Russkiy meditsinskiy zhurnal. Meditsinskoye obozreniye = Russian Medical Inquiry. 2022;6(8):470–479 (In Russ.)).
EDN: UNBZWA. https://doi.org/10.32364/2587-6821-2022-6-8-470-479
12. Zhang S, Wang Y, Cheng J, Huangfu N, Zhao R, Xu Z et al. Hyperuricemia and cardiovascular disease. Curr Pharm Des. 2019;25(6):700–9.
PMID: 30961478. https://doi.org/10.2174/1381612825666190408122557
13. Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1–11.
PMID: 32739239. https://doi.org/10.1016/j.ejim.2020.07.006
14. Li D, Wang D, Dai X, Ni Y, Xu X. Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study. Front Public Health. 2022;10:1012223.
PMID: 36388339. PMCID: PMC9644181. https://doi.org/10.3389/fpubh.2022.1012223
15. Блинова Н.В., Трушина О.Ю., Кисляк О.А., Подзолков В.И., Брагина А.Е., Чазова И.Е. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2025. Системные гипертензии. 2025;22(2):5–17. (Blinova NV, Trushina OIu, Kislyak OA, Podzolkov VI, Bragina AE, Chazova IE. Consensus on the management of patients with hyperuricemia and high cardiovascular risk: 2025. Sistemnye gipertenzii = Systemic Hypertension. 2025;22(2):5–17 (In Russ.)).
EDN: GDXVCF. https://doi.org/10.38109/2075-082X-2025-2-5-17
16. Чазова И.Е., Жернакова Ю.В., Кисляк О.А., Подзолков В.И., Ощепкова Е.В., Миронова О.Ю., Блинова Н.В. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2022. Системные гипертензии. 2022;19(1):5–22. (Chazova IE, Zhernakova YuV, Kislyak OA, Podzolkov VI, Oshchepkova EV, Mironova OYu, Blinova NV. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Sistemnye gipertenzii = Systemic Hypertension. 2022;19(1):5–22 (In Russ.)).
EDN: HBLVVV. https://doi.org/10.38109/2075-082X-2022-1-5-22
17. Чазова И.Е., Жернакова Ю.В., Кисляк О.А., Недогода С.В., Подзолков В.И., Ощепкова Е.В. с соавт. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском. Системные гипертензии. 2019;16(4):8–21. (Chazova IE, Zhernakova YuV, Kislyak OA, Nedogoda SV, Podzolkov VI, Oshchepkova EV et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment. Sistemnye gipertenzii = Systemic Hypertension. 2019;16(4):8–21 (In Russ.)).
EDN: HSKPCZ. https://doi.org/10.26442/2075082X.2019.4.190686
18. Borghi C, Domienik-Karłowicz J, Tykarski A, Filipiak KJ, Jaguszewski MJ, Narkiewicz K et al. Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update. Cardiol J. 2024;31(1):1–14.
PMID: 38155566. PMCID: PMC10919576. https://doi.org/10.5603/cj.98254
19. Borghi C, Domienik-Karłowicz J, Tykarski A, Widecka K, Filipiak KJ, Jaguszewski MJ et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J. 2021;28(1):1–14.
PMID: 33438180. PMCID: PMC8105060. https://doi.org/10.5603/CJ.a2021.0001
20. Borghi C, Tykarski A, Widecka K, Filipiak KJ, Domienik-Karłowicz J, Kostka-Jeziorny K et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J. 2018;25(5):545–63.
PMID: 30394510. https://doi.org/10.5603/CJ.2018.0116
21. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci. 2021;22(17):9221.
PMID: 34502127. PMCID: PMC8431537. https://doi.org/10.3390/ijms22179221
22. Chi X, Cen Y, Yang B, Zhang H, Pu Z, Feng J et al. Effects of dietary factors on hyperuricaemia and gout: A systematic review and meta-analysis of observational studies. Int J Food Sci Nutr. 2024;75(8):753–73.
PMID: 39289820. https://doi.org/10.1080/09637486.2024.2400489
23. Schlesinger N. Dietary factors and hyperuricaemia. Curr Pharm Des. 2005;11(32):4133–38.
PMID: 16375734. https://doi.org/10.2174/138161205774913273
24. Zhang T, Liu W, Gao S. Exercise and hyperuricemia: An opinion article. Ann Med. 2024;56(1):2396075.
PMID: 39183708. PMCID: PMC11348809. https://doi.org/10.1080/07853890.2024.2396075
25. Valsaraj R, Singh AK, Gangopadhyay KK, Ghoshdastidar B, Goyal G, Batin M et al. Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement. Diabetes Metab Syndr. 2020;14(2):93–100.
PMID: 31991299. https://doi.org/10.1016/j.dsx.2020.01.007
26. Viggiano D, Gigliotti G, Vallone G, Giammarino A, Nigro M, Capasso G. Urate-lowering agents in asymptomatic hyperuricemia: Role of urine sediment analysis and musculoskeletal ultrasound. Kidney Blood Press Res. 2018;43(2):606–15.
PMID: 29689561. https://doi.org/10.1159/000489145
27. Yu KH, Chen DY, Chen JH, Chen SY, Chen SM, Cheng TT et al. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. Int J Rheum Dis. 2018;21(4):772–87.
PMID: 29363262. https://doi.org/10.1111/1756-185X.13266
28. Skoczynska M, Chowaniec M, Szymczak A, Langner-Hetmanczuk A, Maciązek-Chyra B, Wiland P. Pathophysiology of hyperuricemia and its clinical significance – a narrative review. Reumatologia. 2020;58(5):312–23.
PMID: 33227090. PMCID: PMC7667948. https://doi.org/10.5114/reum.2020.100140
29. Hisatome I, Li P, Miake J, Taufiq F, Mahati E, Maharani N et al. Uric acid as a risk factor for chronic kidney disease and cardiovascular disease – Japanese guideline on the management of asymptomatic hyperuricemia. Circ J. 2021;85(2):130–38.
PMID: 33342914. https://doi.org/10.1253/circj.CJ-20-0406
30. Sun M, Lyu Z, Wang C, Li Y, Zhao D, Ran X et al. 2024 update of Chinese guidelines for diagnosis and treatment of hyperuricemia and gout part I: Recommendations for general patients. Int J Rheum Dis. 2025;28(7):e70375.
PMID: 40692263. PMCID: PMC12280528. https://doi.org/10.1111/1756-185x.70375
31. Li C, Lu J, Lyu Z, Chen H, Su B, Ban B et al. Clinical Practice Consensus Statement 2025: Management of hyperuricemia and gout in adolescents. Int J Rheum Dis. 2025;28(7):e70378.
PMID: 40693733. PMCID: PMC12282318. https://doi.org/10.1111/1756-185x.70378
32. Клинические рекомендации. Артериальная гипертензия у взрослых. Общероссийская общественная организация «Российское кардиологическое общество», общероссийская общественная организация «Российское научное медицинское общество терапевтов». Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 62_3. Доступ: https://cr.minzdrav.gov.ru/view-cr/62_3 (дата обращения – 21.11.2025). (Clinical guidelines. Arterial hypertension in adults. Russian Society of Cardiology, Russian Scientific Medical Society of Internal Medicine. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 62_3. URL: https://cr.minzdrav.gov.ru/view-cr/62_3 (date of access – 21.11.2025) (In Russ.)).
33. Клинические рекомендации. Хроническая сердечная недостаточность. Общероссийская общественная организация «Российское кардиологическое общество», общероссийская общественная организация «Общество специалистов по сердечной недостаточности», автономная некоммерческая организация «Национальное общество по изучению сердечной недостаточности и заболеваний миокарда», общероссийская общественная организация «Российское научное медицинское общество терапевтов». Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 156_2. Доступ: https://cr.minzdrav.gov.ru/view-cr/156_2 (дата обращения – 21.11.2025). (Clinical guidelines. Chronic heart failure. Russian Society of Cardiology, Russian Heart Failure Society, National Society for the Study of Heart Failure and Myocardial Diseases, Russian Scientific Medical Society of Internal Medicine. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 156_2.
URL: https://cr.minzdrav.gov.ru/view-cr/156_2 (date of access – 21.11.2025) (In Russ.)).
34. Клинические рекомендации. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Ассоциация сердечно-сосудистых хирургов России, общероссийская общественная организация «Российское кардиологическое общество», Ассоциация ревматологов России, Российское медицинское общество по артериальной гипертонии, общероссийская общественная организация содействия развитию лучевой диагностики и терапии «Российское общество рентгенологов и радиологов», Российское респираторное общество, Евразийская ассоциация кардиологов, Российское общество анестезиологов и реаниматологов. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 159_2. Доступ: https://cr.minzdrav.gov.ru/view-cr/159_2 (дата обращения – 21.11.2025). (Clinical guidelines. Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Association of Cardiovascular Surgeons of Russia, Russian Society of Cardiology, Association of Rheumatologists of Russia, Russian Medical Society for Arterial Hypertension, Russian Society of Roentgenologists and Radiologists, Russian Respiratory Society, Eurasian Association of Cardiology, Russian Society of Anesthesiologists and Resuscitators. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 159_2.
URL: https://cr.minzdrav.gov.ru/view-cr/159_2 (date of access – 21.11.2025) (In Russ.)).
35. Клинические рекомендации. Хроническая болезнь почек (ХБП). Национальная ассоциация нефрологов. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 469_3. Доступ: https://cr.minzdrav.gov.ru/view-cr/469_3 (дата обращения – 21.11.2025). (Clinical guidelines. Chronic kidney disease (CKD). National Association of Nephrology. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 469_3.
URL: https://cr.minzdrav.gov.ru/view-cr/469_3 (date of access – 21.11.2025) (In Russ.)).
36. Клинические рекомендации. Сахарный диабет 2 типа у взрослых. Российская ассоциация эндокринологов. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 290_2. Доступ: https://cr.minzdrav.gov.ru/view-cr/290_2 (дата обращения – 21.11.2025). (Clinical guidelines. Type 2 diabetes mellitus in adults. Russian Association of Endocrinology. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 290_2. URL: https://cr.minzdrav.gov.ru/view-cr/290_2 (date of access – 21.11.2025) (In Russ.)).
37. Клинические рекомендации. Ожирение. Российская ассоциация эндокринологов, Общество бариатрических хирургов. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 28_3. Доступ: https://cr.minzdrav.gov.ru/view-cr/28_3 (дата обращения – 21.11.2025). (Clinical guidelines. Obesity. Russian Association of Endocrinology, Society of Bariatric Surgery. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 28_3. URL: https://cr.minzdrav.gov.ru/view-cr/28_3 (date of access – 21.11.2025) (In Russ.)).
Similar Articles
